Target detail
MET
MET proto-oncogene, receptor tyrosine kinase
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: MET proto-oncogene, receptor tyrosine kinase
Aliases: MET, MET proto-oncogene, receptor tyrosine kinase
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000105976
Index freshness: last_synced_at 2026-05-15T19:10:24.329+00:00 · updated 2026-05-15T19:10:24.758329+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for MET. Empty groups mean no matching rows — not a claim about biology or clinical use.
- ClinicalTrials.govLive when indexed
Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
Rows from disease_target_evidence for this symbol.
glioblastoma
affected_pathway,literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
No linked drug rows
When drug_targets and drugs rows exist for this symbol, they are listed here.
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
NCT00813943 — Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02223052 — Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT05909618 — Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT02502708 — Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02177578 — Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov
Open trials hubNCT04209790 — Neoadjuvant Chemoradiation for Resectable Glioblastoma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT01124240 — Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
Status: UNKNOWN · clinicaltrials.gov
Open trials hubNCT06059690 — Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT07552233 — NK Cell Therapy for Malignant Solid Brain Tumors
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT01631552 — Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01849146 — Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT03107780 — Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT00433381 — Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00255671 — Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00624728 — Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00584883 — A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01607905 — Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02179086 — Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov
Open trials hubNCT02661282 — Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02311920 — Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00006246 — Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT06492486 — Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Status: NOT_YET_RECRUITING · clinicaltrials.gov
Open trials hubNCT06160596 — Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT07387666 — Imaging Acetadote Metabolism in Glioblastoma
Status: NOT_YET_RECRUITING · clinicaltrials.gov
Open trials hubNCT02431572 — A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT03633552 — Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma
Status: UNKNOWN · clinicaltrials.gov
Open trials hubNCT04945148 — Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT06710249 — Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT00402116 — Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT07485049 — BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT04143425 — Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT03687034 — A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma
Status: UNKNOWN · clinicaltrials.gov
Open trials hubNCT07521657 — Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Status: NOT_YET_RECRUITING · clinicaltrials.gov
Open trials hubNCT03367715 — Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT04541225 — Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT02717962 — Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT03370926 — FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
Status: UNKNOWN · clinicaltrials.gov
Open trials hubNCT00884741 — Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT06359379 — Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT04908176 — A Drug-drug Interaction Study of Avapritinib and Midazolam
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT05131815 — The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01870726 — Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT01430351 — Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT05843253 — Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT01873469 — Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT06499831 — 18F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain Gliomas
Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov
Open trials hubRepurposing signal rows for drugs linked to this target via drug_targets.
No research signals for linked drugs
Run the deterministic signal builder after drug_targets and source rows are present.
Structured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
- clinicaltrials.gov: 46
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
No matching live evidence found
When repurposing_signal rows reference this marker via linked drugs, summaries appear here.